Pharma Pipelines Filling, Firms Say; New Fear Is “Bottleneck” In Early Stage

Large pharma companies are facing a potential "bottleneck" in early stage clinical development as they sift through new therapeutic candidates, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, told a BIO-Windhover conference April 15 in Washington, D.C